| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 1.222 | 8.669 | 8.750 | 9.439 | 10.873 | 11.419 |
| Total Income - EUR | - | - | - | - | 1.222 | 8.669 | 8.754 | 9.439 | 10.873 | 11.419 |
| Total Expenses - EUR | - | - | - | - | 684 | 3.681 | 2.805 | 4.933 | 4.587 | 3.495 |
| Gross Profit/Loss - EUR | - | - | - | - | 538 | 4.989 | 5.948 | 4.506 | 6.286 | 7.925 |
| Net Profit/Loss - EUR | - | - | - | - | 501 | 4.749 | 5.718 | 4.265 | 5.418 | 6.847 |
| Employees | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Kormedexcent S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 51 | 965 | 1.066 | 1.026 | 2.166 | 1.098 |
| Current Assets | - | - | - | - | 1.266 | 5.207 | 5.629 | 5.847 | 5.695 | 9.173 |
| Inventories | - | - | - | - | 0 | 492 | 0 | 0 | 27 | 0 |
| Receivables | - | - | - | - | 0 | 0 | 0 | 0 | 650 | 28 |
| Cash | - | - | - | - | 1.266 | 4.715 | 5.629 | 5.847 | 5.017 | 9.144 |
| Shareholders Funds | - | - | - | - | 543 | 5.281 | 6.626 | 5.437 | 7.618 | 10.270 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 774 | 890 | 68 | 1.436 | 243 | 0 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Kormedexcent S.r.l.